Navigation Links
Essentialis Appoints Mahendra G. Shah, Ph.D., to Board of Directors
Date:1/5/2012

SAN DIEGO, Jan. 5, 2012 /PRNewswire/ -- Essentialis, Inc., today announced the appointment of Mahendra G. Shah, Ph.D., a partner with the life sciences-focused venture capital firm Vivo Ventures, to its Board of Directors.  A biopharma executive noted for his expertise in business development and economic strategies, Dr. Shah becomes the sixth member of the Board of Directors for Essentialis, a company focused on the development of a breakthrough medicine for the treatment of cardiovascular and metabolic disease.  Its lead compound, DCCR, is now in Phase IIb trials for patients with very high triglycerides. 

"Dr. Shah brings to Essentialis his tested knowledge in business development, clinical design and pharma-board leadership," said Stuart Collinson, Ph.D., Chairman of the Board, Essentialis.  "Essentialis expects to release its Phase IIb trial data for DCCR in the coming weeks.  As we prepare to begin a new chapter with an exciting new compound for further evaluation, board members with Dr. Shah's range of experience will advance our development objectives."

Essentialis added Dr. Richard Pasternak, a renowned cardiologist and former Merck & Co., Inc. executive, and Mr. Aaron Berg, Essentialis president, who was recently promoted to Chief Executive Officer, to its board of directors in December 2011.

About Mahendra G. Shah, Ph.D.

Mahendra G, Shah, Ph.D., has been a venture partner at Vivo Ventures, a life sciences-focused venture fund, since March 2010.  Prior to joining Vivo Ventures, he served as chief executive for several biopharma companies.  From September 2005 to December 2009, he was the founder, chairman and CEO of Nextwave Pharmaceuticals Pediatric, a specialty biomedical company.  From 1993 to 2003, he served as chairman and CEO of First Horizon Pharmaceuticals, a publicly traded specialty pharmaceutical company, where he raised more than $200 million in the public market and built a profitable company with sales exceeding $150 million.  Achieving its business objectives, First Horizon (renamed Sciele) was acquired by Shionogi Pharmaceutical Company for $1.4 billion in 2008.  Dr. Shah also served as the senior director of new business development with Fujisawa USA (Astellas) from 1987 to 1991; prior to that, he served in scientific and management positions with Schering-Plough and Bristol Myers-Squibb Company.

Dr. Shah has served on the boards of Unimed Pharmaceuticals (UMED), Introgen Therapeutics Inc., Inpharmakon, Inc., Protomed Inc., Structural Bioinformatics Inc., and Zarix Inc. He received his Ph.D. in industrial pharmacy from St. John's University and his Bachelors and Masters Degree in Pharmacy from L.M. College of Pharmacy in Gujarat, India.

About DCCR

DCCR is a proprietary crystalline salt of diazoxide in a controlled-release, once-a-day tablet formulation, currently in development for patients with very high triglycerides. Essentialis expects to initiate Phase III clinical trials in 2012.  DCCR is covered by multiple issued US patents, which provide composition of matter protection until 2028.  Essentialis has evaluated DCCR in double-blind, placebo-controlled studies that demonstrated the drug was well tolerated, and achieved various statistically significant endpoints in patients with elevated triglycerides. More than 100,000 patient-years of treatment with diazoxide during the last 40 years, and more than 3,000 peer reviewed publications covering in-vitro, animal model and clinical results with diazoxide, support the acceptable safety of DCCR.

About Essentialis, Inc.

Essentialis is a San Diego-headquartered pharmaceutical company focused on the development of breakthrough medicines targeted to the ATP-sensitive potassium channel, a metabolically regulated membrane protein whose modulation has potential to treat and prevent a wide range of cardiovascular and metabolic diseases.  For more information visit http://essentialistherapeutics.com/

Contacts:

Kristie Kuhl
kkuhl@makovsky.com 
212-508-9642

Or

Aaron Berg
aberg@essentialistherapeutics.com 
858-964-5022


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Promotes Aaron Berg to Chief Executive Officer
2. Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
3. Essentialis to Submit SPA for Hypertriglyceridemia
4. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
5. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
6. PrimeraDx Appoints David Jackson as VP of Business Development
7. China Health Resource Appoints USA Acquisition Counsel
8. Winner Medical Appoints BDO China as Independent Auditor
9. Marken Appoints New Head of Global Quality Assurance
10. Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board
11. Qforma Appoints Ian McGuinness as Vice President, Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- Transportation Insight, a multi-modal lead logistics solutions provider receives ... with expertise serving clients in the food industry. Vice ... was named a 2017 Food Logistics Champion: ... publication exclusively dedicated to covering the movement of product ... has brought to Transportation Insight a wealth of knowledge ...
(Date:3/23/2017)... Calif. and INDIANAPOLIS , ... LLY ) and the William Sansum Diabetes ... lives of Latino people affected by diabetes through enhanced ... burden of diabetes and cardiovascular disease bears a disproportionate ... States ," said David Kerr , M.D., ...
(Date:3/23/2017)... , March 23, 2017  The U.S. Food and ... for the treatment of adults and pediatric patients 12 ... including those who have not received prior chemotherapy. This ... rare, aggressive form of skin cancer. "While ... patients with a rare form called Merkel cell cancer ...
Breaking Medicine Technology:
(Date:3/24/2017)... Orion, MI (PRWEB) , ... March 24, 2017 ... ... insurance assistance, financial planning, and related services to families and business owners across ... initiative aimed at feeding regional families struggling with financial difficulties. , The Oxford/Orion ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... that they are now offering treatments for sleep apnea and TMJ at their ... Sleep apnea , specifically the obstructive type, is increasingly being treated at ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ( ... patients for colonoscopy at the HyGIeaCare® Center that is to be located adjacent ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration ...
(Date:3/24/2017)... ... ... “End Time GPS”: a dauntless and enlightened study of the second-coming ... the creation of published author, Wesley Gerboth, a World War II veteran, with a ... Now, at age ninety-one, he shares the Wisdom God bestowed upon him in this ...
(Date:3/23/2017)... , ... March 23, 2017 , ... In 2016 the ... estimates that there could be four million Zika-related cases in the Americas within the ... numbers of US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, ...
Breaking Medicine News(10 mins):